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A series of mitochondria-targeted antioxidants comprising a lipophilic triphenylphosphonium cation
attached to the antioxidant chroman moiety of vitamin E by an alkyl linker have been prepared. The
synthesis of a series of mitochondria-targeted vitamin E derivatives with a range of alkyl linkers gave
compounds of different hydrophobicities. This work will enable the dependence of antioxidant defence
on hydrophobicity to be determined in vivo.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Mitochondria are essential to the functioning of most eukaryotic
cells because they provide the energy necessary for cell activities in
the form of an elevated adenosine triphosphate/diphosphate ratio
by oxidative phosphorylation.1 Because free radicals are produced as
a side product of this respiration, mitochondrial localised oxidative
damage accumulates faster than in the rest of the cell. Mitochondrial
dysfunction due to oxidative damage has been implicated in a wide
range of conditions from ageing,2e4 ischaemia-reperfusion injury,5e7
cancer,8e10 epilepsy11 and to neurodegenerative diseases12e15 such
as amyotrophic lateral sclerosis16 and Alzheimer’s17,18 and Parkin-
son’s19 diseases. Because of the roles mitochondria play in a wide
range of pathologies, the engineering of molecules to prevent mi-
tochondrial oxidative damage has therapeutic potential.20
Attaching a bioactive moiety to a lipophilic cation, such as tri-
phenylphosphonium (TPP), enables non-mediated, membrane po-
tential driven, accumulation of the active group within the
mitochondrial matrix.21e23 These molecules have been shown to
actively accumulate within mitochondria in tissues following oral
delivery.24 Numerous examples in the literature, including
in vitro,22,23,25e27 ex vivo,28 in vivo29 as well as human trials30 havemail address: pm@mrc-mbu.
r Ltd. This is an open access articldemonstrated that mitochondria-targeted antioxidants are signif-
icantly more effective than non-targeted analogues at preventing
mitochondrial oxidative damage in a range of pathologies.
To date, mitochondria-targeted antioxidants based on the nat-
ural antioxidants Coenzyme Q,22 lipoic acid,31 and vitamin E23 have
been synthesised. A series of compounds based on coenzyme Q (viz.
MitoQ) have been synthesised with 3-,21 5-,21 10-21,22 and 15-
carbon21 alkyl chains linking the TPP and quinone functional
groups (MitoQ3e15). This set of compounds displayed a wide range
of lipophilicities21 and there was signiﬁcant dependence of the
protective behaviour in vitro on the linking chain length.32 The
maximum antioxidant efﬁcacy for the MitoQn series against mito-
chondrial oxidative damage was obtained with a 10-carbon alkyl
chain (viz. MitoQ10). This intriguing chain-length dependence was
found to be due to increased hydrophobicity which enhanced the
extent of uptake into mitochondria by favouring adsorption to the
mitochondrial inner membrane; longer linker chain-length which
allowed the antioxidant quinol moiety to penetrate deeper into the
core of the mitochondrial inner membrane relative to the TPP
moietydwhich was localized close to the membrane surface; and
longer chain length which allowed access of the ubiquinonemoiety
to the active site of mitochondrial complex II thereby facilitating its
rapid reduction to the active ubiquinol antioxidant.32 Only one
targeted vitamin E molecule (MitoE) has been reported to date and
this contains a 2-carbon chain linking the functional, antioxidant
chromanmoiety of vitamin E to the targeting TPP cation and is thuse under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Scheme 1. Synthesis of key hydroxychromans for MitoE2, MitoE4 and MitoE6. Reagents
and conditions: a HgO, Tf2O, CH3CN (10 min), tetramethylurea (5 min), H2O, CH2Cl2;
b DHP, PPTS, CH2Cl2; c vinylMgCl, THF; d HCOOH, 10, reﬂux.
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compound depended on alkyl chain length, we have carried out
a synthetic study to obtain mitochondria-targeted compounds
based on vitamin E with varying alkyl chain lengths, and conse-
quently varying lipophilicities. Previously some of the compounds
obtained from this study have been used to create a series of vi-
tamin E succinate derivatives to assay for anticancer activity33 and
this report also provides full experimental support for the pre-
cursors involved in that work.
The previous synthesis23,25 of MitoE2 involved a large number of
steps, was not amenable to the creation of analogues, and was not
adaptable to scale-up. Retrosynthetic analysis of a generic MitoEn
with chain length n (A) (Fig. 1) shows it can be formed from B by
displacement of a leaving group Y. The structure B is the key in-
termediate in the synthetic scheme as this establishes the basic
carbon framework of the target molecule. The substituted hetero-
cyclic ring in B can be derived from 2,3,5-trimethyl-p-hydroqui-
none (C) and a tertiary allylic alcohol (D) which in turn can be
derived from a methyl ketone (E) and a vinyl organometallic spe-
cies (F). The appropriate methyl ketone (E) can be formed from the
corresponding u-hydroxy alkyne (G).Fig. 1. Retrosynthetic analysis of MitoEn.
Scheme 2. Syntheses of MitoE2, MitoE4 and MitoE6. Reagents and conditions: a MsCl,
Et3N, CH2Cl2; b PPh3, 80 C (21 and 23); c PPh3, NaI, 90 C (25); d LDA, THF.As a variety of u-hydroxy alkynes are available, especially by
utilising acetylene zipper chemistry,31 this provides the required
ﬂexibility to form any MitoEn. Using this general approach we re-
port the synthesis of MitoEn as the mesylate salts with n¼2, 4, 6 (1,
2, 3) and also MitoE10 (4) and MitoE11 (5) using related chemistry.
O
HO
P+
-OMs
n
1 n = 2
2 n = 4
3 n = 6
4 n = 10
5 n = 11
2. Results and discussion
The synthesis of MitoE6 (3) (Scheme 2), will be described in
detail as an exemplar of the methodology. For this the required u-
Fig. 2. (A) Numbering scheme for assignment of NMR spectra of MitoEn. (B) Key HeH
correlations: gCOSY, NOESY. (C) Key HeC correlations: HMBC, mutual
HMBC.
Table 1
Selected 1H NMR resonances in the MitoE mesylate series
Assignment MitoE2 MitoE4 MitoE6 MitoE10
da da da da
4 2.44b, 2.58b 2.55c 2.55c 2.56c
9 2.06 2.07 2.07 2.06
10 2.15 2.08 2.10 2.10
11 2.03 1.94 2.00 2.04
12 1.37 1.18 1.17 1.20
10 1.74b, 1.98b 1.54b 1.50b 1.52b
n0d 3.13b, 3.37b 3.19b 3.26b 3.28b
OMs 2.60 2.66 2.50 2.53
a Chemical shift in CD2Cl2 referenced to solvent (5.31 ppm).
b Value of d at centre of multiplet.
c Triplet (J¼6.8 Hz).
d Methylene adjacent to Pþ.
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Hg(OTf)2$(TMU)2 in aqueous CH3CN34 to afford 8-hydroxy-2-
octanone (7) in 95% yield (Scheme 1). The primary hydroxyl
groupwas then converted into a THP ether (8) in 86% yield followed
by reaction with vinylmagnesium chloride to readily afford the
tertiary allylic alcohol 9, following chromatography with 0.1% Et3N
in the elutant, in 96% yield. Reaction of 9 with 2,3,5-trimethyl-p-
hydroquinone (10) in acid35dpreferably formic acid36dafforded
diol 11 in 53% yield.
The synthesis of MitoE2 and MitoE4 followed the same basic
route although some speciﬁc modiﬁcations for producing the key
intermediate allylic tertiary alcohol precursors (14,19) were re-
quired reﬂecting availability of suitable starting materials or un-
desired intramolecular reactions. Thus the synthesis of the MitoE2
hydroxychroman intermediate (15, Scheme 1) was completed
starting with 4-hydroxy-2-butanone (12) and proceeding via the
THP ether (13) and tertiary allylic alcohol (14). The synthesis of
MitoE4 required the use of 5-hexyn-1-ol (16) as the starting ma-
terial. Reaction of 16 with aqueous Hg(OTf)2$(TMU)2 resulted in
signiﬁcant formation of the cyclic hemiketal, 2-methyl-tetrahydro-
2H-pyran-2-ol.37 To overcome this undesired cyclization the pri-
mary alcohol was converted to an acetate (17) before trans-
formation into the acetoxy methyl ketone (18).32 Treatment of 18
with excess vinylmagnesium chloride simultaneously formed the
required tertiary allylic alcohol functionality and hydrolysed the
acetate ester affording 19.
Preliminary studies on the formation of triphenylphosphonium
salts from chromanols with an appropriate primary leaving group
and triphenylphosphine showed substantial degradation of the
heterocyclic system, particularly when the rate of phosphonium
salt formation was relatively slow. While the nature of these un-
desired side reactions was not fully elucidated it was considered
useful to protect the electron rich phenol function with an electron
withdrawing group during phosphonium salt formation. There are
several literature reports of the use of the methanesulfonyl (mesyl)
group to protect phenols with subsequent removal using basic re-
agents.38 The mesyl group can therefore serve two functions, as an
electrophilic activator of the primary alcohol by forming a mesy-
loxy group while also providing phenol protection during phos-
phonium salt formation.
Diol 11was treatedwith two equivalents of MsCl in the presence
of Et3N and afforded the bis-mesylate 21 in 78% yield (Scheme 2).
The bis-mesylate was then reacted with PPh3 at 90 C for 48 h to
give 22 in 92% yield. Removal of the aryl mesyl ester was trialled
with the mesyl derivative of vitamin E and, while reactions using
NaBH4, Cs2CO3 or MeONa/MeOH showed no change, reaction with
three equivalents of LDA resulted in complete conversion to the
phenol vitamin E (Supplementary data). To compensate for the
likely ylide formation with the phosphonium substrates, the
amount of LDA used in the reaction with 22 was increased to
6 equiv and this protocol afforded MitoE6 (3) mesylate in 49% yield.
The synthesis of MitoE4 (2) mesylate was also completed from
20 following the same sequence (viz. 20/23/24/2) (Scheme 2).
For the synthesis of MitoE2 (1) the bis-mesylate (25) was readily
obtained from 15, but direct reaction of 25 with PPh3 at 80e90 C
produced no phosphonium salt. However addition of 5 equiv of NaI
to the melt gave 26, which was then treated with LDA to afford
MitoE2 (1) mesylate after anion exchange.
During the developmental phase the syntheses of MitoE10 (4)
andMitoE11 (5) as themesylate salts were also completed using less
efﬁcient earlier variations on the optimised route presented above
(Supplementary data). MitoE10 (4) was synthesised starting from 1-
hydroxy-11-dodecyne, obtained by the addition of 1-bromononane
to lithiated propargyl THP ether followed by triple bond migration
using NaH and ethylenediamine.39 In both cases the ﬁnal step in-
volved reaction of triphenylphosphine with the mesyloxy phenol(S7, S11, Supplementary data) and the adverse effects of extended
exposure of the unprotected phenol moiety to these reaction con-
ditions was evident.
The NMR spectra for the mesylates MitoE2 (1), MitoE4 (2),
MitoE6 (3), MitoE10 (4) and MitoE11 (5) displayed a number of
common features which are summarized in Fig. 2 and Table 1. As an
example the 1H NMR spectrum of MitoE6 (3) contained a triplet at
d 2.55 (J¼6.8 Hz), consistent with the signal from the methylene
group at position 4. NOESY and gCOSY correlations from this res-
onance to a multiplet at d 1.66e1.80 allowed assignment to the
methylene protons at 3. Both of these signals had NOESY correla-
tions to a 3-proton singlet at d 1.17 therefore assigned to the methyl
protons at 12. The resonances from the aryl methyl groups were
identiﬁed from NOESY correlations as from the protons at 10 (d
2.10) and 11 (d 2.00) and a correlation between the signal from the
remaining methyl group 9 (d 2.07) and the methylene resonance of
4. The signal from the protons at position 60 was clearly evident as
a multiplet at d 3.22e3.30.
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MitoE4, MitoE6 and MitoE10 are summarised in Table 1. The close
proximity of the functional groups in MitoE2 was evident from the
differences compared to the longer chain MitoE compounds.
Further structural conﬁrmation for MitoE2 (1) was provided by
X-ray diffraction of the crystalline bromide (Fig. 3). In this structure,
the sixemembered heterocyclic ring of MitoE2 adopted an enve-
lope conformationwith q¼54.5 (lit.40 54.7) and with C2 deviating
from the O1eC3eC4eC4aeC8a plane by 0.699 A, towards the
phosphonium group.Fig. 3. Perspective view of (1) showing crystallographic numbering.
Fig. 5. Accumulation of MitoE2 and MitoE10 by isolated rat liver mitochondria (Mito)
energised with the respiratory substrate succinate and their release upon dissipa-
tion of the mitochondrial membrane potential with the uncoupler carbonyl cyanide
p-triﬂuoromethoxyphenylhydrazone (FCCP).To determine whether the biochemical properties and antioxi-
dant efﬁcacy of the chromanol moiety of MitoE were affected by
changing the length of alkyl chain conjugating it to the TPP cation,
the ability of the most (MitoE10) and least (MitoE2) lipophilic
members of the MitoEn series to prevent lipid peroxidation was
measured and compared. The ability of the compounds to act as
chain breaking antioxidants in the rat brain homogenate system of
lipid peroxidation23 was assessed. This system was chosen as
comparison of the effects of the antioxidants on preventing lipid
peroxidation would not be confounded by differential uptake into
mitochondria. Rat brain homogenates were allowed to undergo
spontaneous lipid peroxidation, which was assessed by the pro-
duction of thiobarbituric reactive species (TBARS).22 The effect of
MitoE2, and MitoE10 on preventing this peroxidation was then
assessed (Fig. 4) and showed that both compounds were ofFig. 4. Prevention of lipid peroxidation in rat braincomparable efﬁcacy in preventing lipid peroxidation. Therefore it is
concluded that conjugation to the TPP cation by differing alkyl
chain lengths to the chromanol moiety does not signiﬁcantly alter
their intrinsic antioxidant efﬁcacy. Consequently any changes in
antioxidant efﬁcacy seen in mitochondrial or cell studies can be
assigned to differences in uptake, adsorption or recycling. The an-
tioxidant efﬁcacy of theMitoE compounds was far greater than that
of Trolox, which contains the same antioxidant chromanol moiety
as MitoE, connected to a short-chain carboxylic acid rather than
a TPP function, making it far more hydrophilic. This suggests that
the lipophilic nature of the TPP moiety enhances the interaction of
the antioxidant moiety with the phospholipid bilayer.
This aspect was extended by measuring whether MitoE2 and
MitoE10 compounds were accumulated by mitochondria in re-
sponse to the mitochondrial membrane potential, as is expected for
a compound linked to a TPP compound. To measure the uptake of
the MitoE compounds an ion-selective electrode was used that
responds to the concentration of the TPP cation in solution (Fig. 5).homogenates by MitoE compounds and Trolox.
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pension the ion-selective electrode responded to the increase in
concentration of the MitoE compound in the extracellular envi-
ronment. When the mitochondria were energised with the re-
spiratory substrate succinate a largemembrane potential across the
mitochondrial inner membrane was established. This led to the
extensive accumulation of the compounds within mitochondria,
thus lowering the extracellular concentration which is detected by
the electrode. Addition of the uncoupler FCCP resulted in the dis-
sipation of the membrane potential and consequent release of the
compounds back in to the supernatant and this is evident from the
electrode response.
Therefore these experiments showed that, as expected, both
MitoE2 and MitoE10 were taken up by energised mitochondria in
response to the membrane potential. To see if this accumulation
within mitochondria enhanced the ability of the mitochondria-
targeted compounds to decrease oxidative damage to isolated mi-
tochondria the activity was assessed and compared with the anti-
oxidant efﬁcacy of Trolox, a chroman containing antioxidant
molecule, which is not taken up by mitochondria (Fig. 6).Fig. 6. Prevention of lipid peroxidation in rat liver mitochondria by MitoE2, MitoE10 and Trolox.This showed that both MitoE2 and MitoE10 were comparably
protective against mitochondrial lipid peroxidation and that both
were more protective against oxidative damage that Trolox. Finally,
the ability of the most effective version of MitoE, MitoE10 to protect
against oxidative damage to mitochondrial DNA caused by the re-
dox cycling molecule menadione was determined (Fig. 7). This alsoFig. 7. Prevention of oxidative damage to mitochondrial DNA in cells in culture by
MitoE10. The lower the relative ampliﬁcation the greater the damage to DNA.showed that MitoE10 was able to protect against this form of mi-
tochondrial oxidative damage more effectively that the control
compound decylTPP. MitoE2 was not protective in this assay (data
not shown) consistent with the greater protection of MitoE10
against lipid peroxidation.
3. Conclusion
The development of this generalised route to MitoE analogues
has allowed a suite of targeted analogues to be prepared. We have
assessed the biochemical properties of the most (MitoE10) and least
(MitoE2) lipophilic members of the MitoE compounds and found
that they are effective. By analogy with the MitoQ suite of com-
pounds the series ofMitoE compoundswe havemadewill also have
a range of lipophilicities and can be used to assess the effect of
lipophilicity on the biological effects of MitoE. This strategy is both
efﬁcient and can be systematically varied to create a range of MitoE
compounds. These compounds accumulate in mitochondria and
preliminary biological data demonstrate that MitoE analogues
show greater efﬁcacy in preventing lipid peroxidation, mitochon-drial oxidative damage and damage to mitochondrial DNA than
non-targeted compounds. Further work needs to be conducted to
fully understand the trend of biological behaviour of the MitoE
series and determine the activity of the intermediate MitoE com-
pounds and enable the dependence of the antioxidant efﬁcacy of
MitoE on chain length to be assessed in vivo.4. Experimental section
4.1. General procedures
Thin Layer Chromatography (TLC) was performed with silica gel
(Merck) 60F 254 coated on aluminium roll and were developed in
solvent mixtures as indicated. Plates were visualised ﬁrst with UV
light (254 nm) then stained with vanillin or phosphomolybdic acid
and heated. Column chromatography was performed using Merck
60 Silica (200e400 mesh, 40e63 mm) as the adsorbent. Columns
were pre-equilibrated with the starting solvent before use and 50 g
of adsorbent per g of crude product was used. Anion Exchange
Chromatography was performed using Amberlite IRA-400(Cl) ion
exchange resin. The columnwas pre-equilibratedwith 10% aqueous
MsOH before use. Material was loaded in MeOH and the column
was eluted with 1:1 MeOH:H2O.
Nuclear Magnetic Resonance (NMR) Spectroscopy 1H and 13C
NMR spectrawere acquired on a Varian INOVA-300 spectrometer at
7.05 Tand 298 Koperating at 299.90 and 75.42MHz, respectively, or
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at 499.74 MHz and 125.67 MHz, respectively as indicated. 31P NMR
spectrawere acquiredon aVarian INOVA-300 spectrometer at 7.05 T
and 298 K operating at 121.40MHz. Spectrawere acquired in CDCl3,
CD2Cl2 and CD3OD as indicated. The solvent peak was used as an
internal reference for 1H and 13C NMR spectra. In CDCl3 the 1H and
13C NMR spectra were referenced to 7.26 ppm and 77.08 ppm, re-
spectively; in CD2Cl2 1H and 13C NMR spectra were referenced to
5.31 ppm and 53.8 ppm, respectively and CD3OD to 3.31 ppm and
49.0 ppm, respectively. Phosphoric acid (85%) was used as an ex-
ternal reference at 0 ppm for 31P NMR spectra. Spectra were pro-
cessed using standard Varian software. For each 1H NMR signal,
chemical shifts (d), relative integral, multiplicity, coupling constant
(J), and assignment information are given unless otherwise stated.
13C resonances were evident as singlets from a single carbon unless
otherwise stated. The following standard abbreviations are used:
s¼singlet, d¼doublet, t¼triplet, m¼multiplet, dd¼doublet of dou-
blets, td¼triplet of doublets, dt¼doublet of triplets. Standard 2D
experiments (gCOSY, NOESY, HSQC and HMBC) were employed for
assignment of proton and carbon resonances.
Low resolution atmospheric pressure chemical ionisation (APCI)
mass spectroscopy (MS) and low resolution electrospray ionisation
(ESI) MS were performed using a Shimadzu LCMS WP8000a
spectrometer operated in positive or negative ion mode as in-
dicated. High resolution mass spectra (HRMS) were recorded on
a Bruker microTOF-Q spectrometer operated in positive or negative
ion mode as indicated. Data are presented as m/z values for the
parent molecular ion. Combustion microanalyses were performed
by M. Dick or R. McAllister (Campbell Microanalytical Laboratory,
Department of Chemistry, University of Otago).
X-ray diffraction data were collected on a Bruker APEX II CCD
diffractometer, with graphitemonochromatedMo-Ka (l¼0.71073A)
radiation. Intensities were corrected for Lorentz polarisation effects
and a multiscan absorption correction was applied.41 The structure
was solved by direct methods (SIRe9741) and reﬁned on F2 using all
data by full-matrix least-squares procedures (SHELXL 9742).
4.2. Syntheses
4.2.1. General synthetic procedures. Argon was used for reactions
requiring an inert atmosphere. Standard vacuum line Schleck tech-
niques were employed; glassware was ﬂame-dried before use and
cannula were used for transferring liquids between reaction vessels.
Removal of solvents was achieved by either rotary evaporation at
temperaturesofupto50 C,orbyevaporationundera streamofargon.
Some syntheses were carried out a 15 mL Kimax brand round bot-
tomed 10 mm id borosilicate test-tubes ﬁtted with a screw-top that
enables a convenient sealed system under argon to be established.
Diisopropylamine was distilled from NaOH before use. Tri-
ﬂuoromethanesulfonic anhydride (Tf2O) was distilled from P2O5
immediately before use. 2,3,5-Trimethyl-p-hydroquinone (10) was
stirred as a suspension in hexane (10 equiv w/v) was stirred for
30 min. The solvent was removed by ﬁltration and the pale yellow
precipitate was dried at <0.5 mmHg for 2 h. Pyridine was reﬂuxed
over KOH and distilled onto 4 A molecular sieves before use. All
other reagents were used without puriﬁcation.
Absolute alcohol was dried over 4 A molecular sieves. Acetone
was reﬂuxed then distilled onto 3 A molecular sieves. Acetonitrile
(CH3CN) was reﬂuxed over CaH2 and distilled directly before use.
Dichloromethane (CH2Cl2) was reﬂuxed over P2O5 and distilled
onto 3A molecular sieves. Diethyl ether (Et2O) was distilled before
use and stored over sodium wire. Tetrahydrofuran (THF) was
reﬂuxed over KOH then distilled onto Na wire. The pre-dried sol-
vent was then freshly distilled under an argon atmosphere over
a benzophenone-K-Na amalgam (4:1) prior to use. All other sol-
vents were used without puriﬁcation.4.2.2. 9-(Tetrahydro-2H-pyran-2-yloxy)-3-hydroxy-3-methyl-non-
1-ene (9). Vinylmagnesium chloride (1.4 M in THF, 6.3 mL,
8.82 mmol) was added to a solution of 8 (Supplementary data)
(1.006 g, 4.41 mmol) in anhydrous THF (60 mL) stirring at 78 C.
This was stirred for 2 h and then allowed to warm to room tem-
perature over 30 min. To the reaction mixture was added dropwise
saturated aqueous NH4Cl (50 mL) and then this was extracted with
Et2O (350 mL). The combined organic phase was washed with
saturated aqueous NaCl (50 mL), dried over anhydrous MgSO4, ﬁl-
tered and concentrated to give 9 as a pale yellow oil (1.086 g,
4.24 mmol, 96%) which was used without further puriﬁcation.
Analysis calcd for C15H28O3: C 70.3, H 11.0, found: C 70.3, H 10.9;
TLC: Rf 0.37 (1:9 Et2O:CH2Cl2); HRMS (þve ESI) m/z calcd for
[MþNa]þ:279.1931, found: 279.1933; 1H NMR (500 MHz, CD2Cl2):
d (ppm) 1.22 (3H, s,H15), 1.26e1.38 (6H, m,H5eH7), 1.44e1.60 (8H,
m, H4, H8, H11a, H12a, H13), 1.62e1.88 (1H, m, H11b), 1.74e1.82
(1H, m, H13b), 3.33 (1H, td, JHCH¼9.6, JHCCH¼6.7 Hz, H9a),
3.42e3.46 (1H, m, H14a), 3.66 (1H, td, JHCH¼9.6, JHCCH¼6.7 Hz,
H9b), 3.81 (1H, ddd, J¼11.3, 8.3, 3.0 Hz, H14b), 4.52 (1H, t, J¼3.7 Hz,
H10), 5.00 (ABX system, 1H, dd, JAX¼10.7 Hz, JAB¼1.4 Hz, H1a), 5.16
(ABX system, 1H, dd, JBX¼17.4 Hz, JAB¼1.4 Hz, H1b), 5.90 (ABX
system, 1H, dd, JBX¼17.4 Hz, JAX¼10.7 Hz, H2); 13C NMR (125 MHz,
CD2Cl2): d (ppm) 20.1 (C12), 24.2 (C5), 26.0 (C13), 26.6 (C7), 27.9,
27.9 (1C, 2 s, C15), 30.1 (C8), 30.3 (C6), 31.2 (C11), 42.8 (C4), 62.4
(C14), 67.8 (C9), 73.4 (C3), 99.1 (C10), 111.3 (C1), 146.0 (C2).
4.2.3. 2-(6-Hydroxyhexyl)-2,5,7,8-tetramethyl-chromen-6-ol (11). A
solution of 9 (0.959 g, 3.74 mmol) and freshly prepared 2,3,5-
trimethyl-p-hydroquinone (10, 0.460 g, 3.02 mmol) in formic acid
(90 mL) were heated to reﬂux and reﬂuxed for 3 h under an at-
mosphere of argon. The reaction was poured into crushed ice
(w180 mL) and this was extracted with Et2O (3100 mL) under
argon. The combined organic phase was washed with H2O
(3100 mL) under argon, dried over anhydrous MgSO4 and con-
centrated. The oily brown residue was dissolved in MeOH (90 mL),
conc. HCl (0.090 mL) was added and the reaction reﬂuxed for
a further 30 min under argon. The reaction was diluted with ice
cold H2O (200 mL) and this was extracted with Et2O (3100 mL)
under argon. The combined organic phasewas washed under argon
with H2O (3400 mL), saturated aqueous Na2CO3 (3100 mL) and
H2O again (3100 mL), dried over anhydrous MgSO4, ﬁltered and
concentrated to give a brown oil. The crude product was puriﬁed by
column chromatography on silica gel and elution with 1:9
Et2O:CH2Cl2 followed by crystallisation from CH2Cl2 and afforded
11 as a pale yellow solid (0.490 g, 1.60 mmol, 53%). TLC: Rf 0.29 (1:9
Et2O:CH2Cl2); HRMS (þve ESI) m/z calcd for [MþNa]þ: 329.2087,
found: 329.2068; HRMS (ve ESI)m/z calcd for [MH]þ: 305.2122,
found: 305.2135; 1H NMR (500 MHz, CDCl3): d (ppm) 1.22 (3H, s,
H12), 1.28e1.46 (6H, m,H20eH40), 1.28e1.46 (4H, m,H20,H50), 2.105
(3H, s, H11), 2.105 (3H, s, H9), 2.16 (3H, s, H10), 2.60 (2H, t, J¼7.0 Hz,
H4), 3.62 (2H, t, J¼6.3 Hz, H60), 4.2 (1H s (br), H70); 13C NMR
(125MHz, CDCl3): d (ppm) 11.3 (C9), 11.8 (C11), 12.3 (C10), 20.8 (C4),
23.6 (C20), 23.8 (C12), 25.8 (C40), 30.0 (C30), 31.6 (C3), 32.8 (C50), 39.5
(C10), 63.1 (C60), 74.5 (C2), 117.4 (C4a), 118.6 (C5), 121.1, 122.7 (2C, 2
s, C7, C8), 144.6 (C6), 145.6 (C8a).
4.2.4. 5-(Tetrahydro-2H-pyran-2-yloxy)-3-hydroxy-3-methyl-pent-
1-ene (14). Vinylmagnesium chloride (1.40 M in THF, 9.5 mL,
13.3 mmol) was added to a solution of 13 (Supplementary data)
(1.006 g, 5.84 mmol) in anhydrous THF (50 mL) stirring at 78 C.
This was stirred for 2 h and then allowed to warm to room tem-
perature over 30 min. Saturated aqueous NH4Cl (50 mL) was added
dropwise and this was extracted with Et2O (350 mL). The com-
bined organic phase was washed with saturated aqueous NaCl
(50 mL), dried over anhydrous MgSO4, ﬁltered and concentrated to
give a pale yellow oil. The crude product was puriﬁed by column
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containing 0.1% Et3N afforded pure 14 as a colourless liquid (1.091 g,
5.45 mmol, 93%). Analysis calcd for C11H20O3: C 66.0, H 10.1, found:
C 65.9, H 10.2; TLC: Rf 0.71 (1:1 Et2O:CH2Cl2); HRMS (þve ESI) m/z
calcd for [MþNa]þ: 223.1305, found: 223.1305; 1H NMR (500 MHz,
CDCl3): d (ppm) 1.28, 1.29 (3H, 2 s, H11), 1.48e1.63 (4H, m, H7a,
H8a,H9), 1.66e1.82 (3H, m,H4a,H7b,H8b), 1.92e1.99 (1H, m,H4a),
3.47, 3.49 (1H, 2 s, H11), 3.48e3.57 (2H, m, H5a, H10a), 3.79e3.86
(1H, m, H10b), 3.92e3.98 (1H, m, H5b), 4.57, 4.60 (1H, 2 t, J¼7 Hz,
H6), 5.06e5.11, 5.27e5.93 (2H, 2 m, H1), 5.86e5.93 (1H, m, H2);
13C NMR (125MHz, CDCl3): d (ppm) 19.3,19.2 (1C, 2 s, C8), 25.3(5),
25.3(7) (1C, 2 s, C9), 28.6, 28.7 (1C, 2 s, C11), 30.4, 30.6 (1C, 2 s,
C7), 40.2(5), 40.3(2) (1C, 2 s, C4), 61.9, 62.1 (1C, 2 s, C10), 64.9,
65.2 (1C, 2 s, C5), 73.4 (C3), 98.7, 98.9 (1C, 2 s, C6), 112.1, 112.3
(1C, 2 s, C1), 144.6 (C2).
4.2.5. 3,7-Dihydroxy-3-methyl-hept-1-ene (19). Vinylmagnesium
chloride (1.4 M in THF, 40.0 mL, 55.0 mmol) was added to a solution
of 18 (Supplementary data) (1.615 g, 10.21 mmol) in anhydrous THF
(100 mL) stirring at 78 C. This was stirred for 2 h and then
allowed to warm to room temperature over 30 min. To the reaction
mixture was added dropwise aqueous saturated aqueous NH4Cl
(100 mL) and this was extracted with Et2O (3100 mL). The com-
bined organic phase was washed with saturated aqueous NaCl
(100mL), dried over anhydrousMgSO4, ﬁltered and concentrated to
give a yellow oil. Chromatography on silica gel with elution with
1:1 Et2O:CH2Cl2 containing 0.1% Et3N gave 19 as a pale yellow oil
(1.312 g, 9.10 mmol, 89%). Analysis calcd for C8H16O2: C 66.6, H 11.2,
found: C 66.8, H 11.1; TLC: Rf 0.14 (1:1 Et2O:CH2Cl2); HRMS (þve
ESI) m/z calcd for [MþNa]þ: 167.1053, found: 167.1060; 1H NMR
(500 MHz, CD2Cl2): d (ppm) 1.23 (3H, s, H8), 1.32e1.40 (2H, m, H5),
1.46e1.55 (4H, m, H4, H6), 1.89 (2H, s (br), H9, H10), 3.57 (2H, t,
J¼6.3 Hz, H7), 5.01 (ABX system, 1H, dd, JAX¼10.8 Hz, JAB¼1.3 Hz,
H1a), 5.17 (ABX system, 1H, dd, JBX¼17.3 Hz, JAB¼1.3 Hz, H1b), 5.90
(ABX system, 1H, dd, JBX¼17.3 Hz, JAX¼10.8 Hz, H2); 13C NMR
(125MHz, CD2Cl2): d (ppm) 20.4 (C5), 27.9 (C8), 33.4 (C6), 42.2 (C4),
62.7 (C7), 73.4 (C3), 111.5 (C1), 145.8 (C2).
4.2.6. 2-(4-Hydroxybutyl)-2,5,7,8-tetramethyl-chromen-6-ol (20). A
solution of 19 (1.062 g, 7.37 mmol) and freshly prepared 2,3,5-
trimethyl-p-hydroquinone (10, 1.031 g, 6.78 mmol) in formic acid
(200 mL) were heated to reﬂux and reﬂuxed for 3 h under an at-
mosphere of argon. The reaction was poured onto crushed ice
(w600 mL) and this was extracted with Et2O (3200 mL) under
argon. The combined organic phase was washed with H2O
(3200 mL) under argon, dried over anhydrous MgSO4 and con-
centrated. The oily brown residuewas dissolved inMeOH (200mL),
conc. HCl (0.200 mL) was added and the reaction reﬂuxed for
a further 30 min under argon. The reaction was diluted with ice-
cold H2O (400 mL) and this was extracted with Et2O (3200 mL)
under argon. The combined organic phasewas washed under argon
with H2O (3200 mL), saturated aqueous Na2CO3 (3200 mL) and
H2O again (3200 mL), dried over anhydrous MgSO4, ﬁltered and
concentrated to give a brown oil. Column chromatography on silica
gel and elution with 1:9 Et2O:CH2Cl2 afforded 20 which recrystal-
lised from CH2Cl2 to give a pale yellow solid (1.061 g, 3.81 mmol,
52%). Analysis calcd for C17H26O3: C 73.3, H 9.4, found: C 73.3, H 9.5;
TLC: Rf 0.21 (1:9 Et2O:CH2Cl2), Rf 0.07 (1:4 EtOAc:petroleum ether
40e60); mp 102.7 C; HRMS (þve ESI) m/z calcd for [MþNa]þ:
301.1774, found: 301.1769; 1H NMR (500MHz, CD2Cl2): d (ppm) 1.21
(3H, s, H12), 1.42e1.65 (6H, m, H10eH30), 1.72e1.82 (2H, m, H3),
2.065 (3H, s, H11), 2.073 (3H, s, H9), 2.12 (3H, s, H10), 2.58 (2H, t,
J¼7.0 Hz, H4), 3.59 (2H, t, J¼6.3 Hz, H40), 4.4 (1H s (br), H100); 13C
NMR (125 MHz, CD2Cl2): d (ppm) 11.4 (C9), 11.9 (C11), 12.3 (C10),
20.3 (C20), 21.0 (C4), 23.8 (C12), 32.0 (C3), 33.7 (C30), 39.7 (C10), 63.1(C40), 74.7 (C2), 117.8 (C4a), 118.9 (C5), 121.3, 122.7 (2C, 2 s, C7, C8),
145.0 (C6), 145.7 (C8a).
4.2.7. 4-(6-Methanesulfonyloxy-2,5,7,8-tetramethyl-chromen-2-yl)
hexyl methanesulfonate (21). A solution of 11 (0.323 g, 1.05 mmol)
and Et3N (0.70 mL, 0.511 g, 5.05 mmol) was stirred in anhydrous
CH2Cl2 (60 mL) at room temperature for 5 min. Methane sulfonyl
chloride (MsCl) (0.20 mL, 0.136 g, 1.19 mmol) was added and the
reaction was stirred for a further 1 h. The reaction mixture was
washed with H2O (550 mL), and saturated aqueous NaHCO3
(50 mL), dried over anhydrous MgSO4, ﬁltered and concentrated in
vacuo to give a yellow oil. The crude oil was puriﬁed by crystal-
lisation from EtOH to give 21 as a white solid (0.378 g, 0.82 mmol,
78%). Analysis calcd for C15H28O3: C 54.5, H 7.4, S 13.9, found: C 54.6,
H 7.5, S 13.8; HRMS (þve ESI) m/z calcd for [MþNa]þ: 485.1638,
found: 485.1633; 1H NMR (500 MHz, CDCl3): d (ppm) 1.23 (3H, s,
H12), 1.31e1.38 (2H, m, H30), 1.38e1.47 (4H, m, H20, H40), 1.49e1.64
(2H, m, H10), 1.71e1.84 (4H, m, H3, H50), 2.09 (3H, s, H11), 2.21 (3H,
s, H9), 2.24 (3H, s, H10), 2.59 (2H, t, J¼6.8 Hz, H4), 2.99 (3H, s, H70),
3.21 (3H, s, H100), 4.21 (2H, t, J¼6.5 Hz, H60); 13C NMR (125 MHz,
CDCl3): d (ppm) 12.0 (C11),13.7 (C9), 14.5 (C10), 20.7 (C4), 23.4 (C20),
23.9 (C12), 25.4 (C40), 29.2 (C50), 29.5 (C30), 31.1 (C3), 37.4 (C70), 38.7
(C100), 39.5 (C10), 70.2 (C60), 75.2 (C2), 118.1 (C4a), 123.8, 128.6 (2C,
2 s, C7, C8), 127.2 (C5), 139.7 (C6), 150.1 (C8a).
4.2.8. (6-(6-Methanesulfonyloxy-2,5,7,8-tetramethyl-chromen-2-yl)
hexyl)triphenylphosphonium methanesulfonate (22). A mixture of
triphenylphosphine (0.671 g, 2.56 mmol) and 21 (0.226 g,
0.49 mmol) in a Kimax tube was ﬂushed with argon, sealed and
stirred at 90 C for 48 h. After cooling the crude product was dis-
solved in CH2Cl2 (0.5 mL) and precipitated from Et2O (20 mL) twice.
The residual solvents were removed to give 22 as a sticky white
solid (0.318 g, 0.44 mmol, 90%). HRMS (þve ESI)m/z calcd for [M]þ:
629.2849, found: 629.2862; 1H NMR (500 MHz, CDCl3): d (ppm)
1.17 (3H, s,H12), 1.22e1.38 (4H, m, H20, H30), 1.41e1.54 (2H, m, H10),
1.54e1.65 (4H, m,H40,H50), 1.67e1.78 (2H, m,H3), 2.01 (3H, s,H11),
2.17 (3H, s,H9), 2.20 (3H, s,H10), 2.54 (2H, t, J¼6.8 Hz,H4), 2.69 (3H
s, H1000), 3.21 (3H s, H100), 3.50e3.60 (2H, m, H60), 7.64e7.72 (6H, m,
H90), 7.74e7.82 (9H, m, H80, H100); 13C NMR (125 MHz, CDCl3):
d (ppm) 11.9 (C11), 13.7 (C9), 14.5 (C10), 20.7 (C4), 21.9 (1C, d,
JCP¼50.0 Hz, C60), 22.6 (1C, d, JCCP¼4.3 Hz, C50), 23.2, 29.6 (2C, 2 s,
C20, C30), 24.0 (C12), 30.3 (1C, d, JC3P¼16.0 Hz, C40), 31.0 (C3), 38.7
(C100), 39.2 (C10), 39.5 (C1000), 75.3 (C2), 118.1 (C4a), 118.6 (1C, d,
JCP¼85.0 Hz, C70), 123.7, 128.6 (2C, 2 s, C7, C8), 127.2 (C5), 130.5
(6C, d, JC3P¼12.3 Hz, C90), 133.6 (6C, d, JCCP¼9.8 Hz, C80), 135.0 (3C, d,
JC4P¼2.9 Hz, C100), 139.6 (C6), 150.1 (C8a); 31P NMR (121 MHz,
CDCl3): d (ppm) 25.6.
4.2.9. 4-(6-Methanesulfonyloxy-2,5,7,8-tetramethyl-chromen-2-yl)
butyl methanesulfonate (23). A solution of 20 (0.468 g, 1.68 mmol)
and Et3N (1.12 mL, 0.818 g, 8.08 mmol) was stirred in anhydrous
CH2Cl2 (30 mL) at room temperature for 5 min. MsCl (0.315 mL,
0.463 g, 4.04 mmol) was added and the solution was stirred for 1 h.
The reactionmixturewaswashedwithH2O (530mL) and saturated
aqueous NaHCO3 (30 mL), dried over anhydrous MgSO4, ﬁltered and
concentrated in vacuo to give a yellow solidwhichwas recrystallised
twice from EtOH to afford 23 as a white solid (0.543 g, 1.25 mmol,
74%). Analysis calcd forC19H30O7S2: C52.5,H7.0, S 14.8, found: C52.5,
H7.3, S 14.6; TLC:Rf0.69 (1:9Et2O:CH2Cl2);HRMS (þve ESI)m/z calcd
for [MþNa]þ: 457.1325, found: 457.1322; 1H NMR (500MHz, CDCl3):
d (ppm) 1.25 (3H, s, H12), 1.52e1.68 (4H, m, H10, H20), 1.74e1.86 (4H,
m,H3, H30), 2.08 (3H, s, H11), 2.21 (3H, s, H9), 2.24 (3H, s,H10), 2.60
(2H, t, J¼7 Hz, H4), 2.98 (3H, s, H50), 3.23 (3H, s, H100), 4.23 (2H, t,
J¼6.5 Hz, H40); 13C NMR (125 MHz, CDCl3): d (ppm) 12.0 (C9), 13.7
(C11), 14.5 (C10), 19.6 (C20), 20.7 (C4), 23.9 (C12), 29.5 (C30), 31.1 (C3),
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(C5), 123.8, 128.8 (2C, 2 s, C7, C8), 139.8 (C6), 150.0 (C8a).
4.2.10. (4-(6-Methanesulfonyloxy-2,5,7,8-tetramethyl-chromen-2-yl)
butyl)triphenyl -phosphonium methanesulfonate (24). A mixture of
23 (0.314 g, 0.72 mmol) and triphenylphosphine (0.981 g,
3.74 mmol) was placed in a Kimax tube, ﬂushed with argon, sealed
and the reaction was stirred as a melt at 90 C for 48 h. The cooled
residue was dissolved in CH2Cl2 (w2 mL) and precipitated from
petroleum ether 40e60 (100 mL) three times. The residual solvents
were removed in vacuo to give 24 as a white solid (0.464 g,
0.67 mmol, 92%). HRMS (þve ESI) m/z calcd for [M]þ: 601.2536,
found: 601.2555; 1H NMR (500 MHz, CDCl3) d (ppm) 1.21 (3H, s,
H12), 1.52e1.59 (2H, m, H10), 1.59e1.82 (6H, m, H3, H20, H30), 1.94
(3H, s, H11), 2.17 (3H, s, H9), 2.19 (3H, s, H10), 2.54 (2H, t, J¼6.8 Hz,
H4), 2.71 (3H, s, H1000), 3.22 (3H, s, H100), 3.48e3.70 (2H, m, H40),
7.65e7.70 (6H, m, H70), 7.74e7.80 (9H, m, H60, H80); 13C NMR
(125MHz) CDCl3: d (ppm) 12.0 (C11), 13.7 (C9), 14.5 (C10), 20.6 (C4),
22.0 (1C, d, JCP¼50.3 Hz, C40), 23.1 (1C, d, JCCP¼4.4 Hz, C30), 24.0
(C12), 24.6 (1C, d, JC3P¼16.1 Hz, C20), 30.9 (C3), 38.7 (C100), 38.8 (C10),
39.6 (C1000), 75.3 (C2), 118.2 (C4a), 118.5 (1C, d, JCP¼85.6 Hz, C50),
123.6, 128.6 (2C, 2 s, C7, C8), 127.3 (C5), 130.5 (1C, d, JC3P¼12.5 Hz,
C70), 133.6 (1C, d, JCCP¼9.9 Hz, C60), 135.0 (1C, d, JC4P¼2.9 Hz, C80),
139.6 (C6), 149.9 (C8a); 31P NMR (121 MHz, CDCl3): d (ppm) 25.5.
4.2.11. 2-(6-(Methanesulfonyloxy)-2,5,7,8-tetramethylchromen-2-yl)
ethyl methanesulfonate (25). A solution of 15 (0.013 g, 0.51 mmol)
and Et3N (424 mL, 0.310 g, 3.06 mmol) was stirred in anhydrous
CH2Cl2 (6mL) at room temperature for 5min. MsCl (88.0 mL, 0.129 g,
1.13 mmol) was added and the reactionwas stirred for a further 1 h.
The reaction mixture was diluted with CH2Cl2 (5 mL). This was
washed with H2O (520 mL), dried over anhydrous MgSO4, ﬁltered
and concentrated in vacuo to give a white solid (0.224 g) which,
after recrystallisation from EtOH to give 25 as white crystals
(0.167 g, 0.41 mmol, 81%). Analysis calcd for C17H26O7S2: C 50.2, H
6.4, S; 15.8, found: C 50.3, H 6.6, S 15.7; TLC: Rf 0.76 (1:9
Et2O:CH2Cl2); mp 126.7 C; HRMS (þve ESI)m/z calcd for [MþNa]þ:
429.1012, found: 429.1002; 1H NMR (500MHz, CDCl3): d (ppm) 1.31
(3H, s, H12), 1.86 (2H, td, J¼7.0, 1.5 Hz, H3), 2.03e2.16 (2H, m, H10),
2.09 (3H, s, H11), 2.21 (3H, s, H9), 2.24 (3H, s, H10), 2.63 (2H, t,
J¼7 Hz, H4), 3.00 (3H, s, H30), 3.24 (3H, s, H100), 4.38e4.52 (2H, m,
H20); 13C NMR (125 MHz, CDCl3): d (ppm) 12.1 (C10), 13.7 (C9), 14.5
(C11), 20.5 (C4), 24.0 (C12), 31.5 (C3), 37.5 (C30), 38.8(0) (C100),
38.8(2) (C10), 66.1 (C20), 73.8 (C2), 117.7 (C4a), 123.9, 129.1 (2C, 2 s,
C7, C8), 127.5 (C5), 140.0 (C6), 149.4 (C8a).
4.2.12. (2-(6-(Methanesulfonyloxy)-2,5,7,8-tetramethyl-2H-chro-
men-2-yl)ethyl)triphenyl-phosphonium methanesulfonate (26). A
mixture of 25 (0.300 g, 0.74 mmol), NaI (0.558 g, 3.74 mmol) and
triphenylphosphine (1.55 g, 3.69 mmol) was ﬂushed with argon in
a Kimax tube then sealed and the reaction was stirred as a melt at
90 C for 48 h. The crude product was dissolved in CH2Cl2 (w2 mL)
and precipitated from petroleum ether 40e60 (100mL) three times.
The product was dissolved in methanol and passed down an anion
exchange column loaded with OMs. The residual solvents were
removed to give 26 as awhite solid (0.450 g, 0.67mmol, 91%). TheUV
spectrum of this compound has been reported previously.23 HRMS
(þve ESI) m/z calcd for [M]þ: 573.2223, found: 573.2225; 1H NMR
(500 MHz, CDCl3): d (ppm) 1.45 (3H, s, H12), 1.88e1.08 (4H, m, H3,
H10), 2.01 (3H, s, H11), 2.12 (3H, s, H9), 2.22 (3H, s, H10), 2.40e2.60
(2H,m,H4), 2.66 (3H, s,H1000), 3.25 (2H, s,H100), 3.26e3.48, 3.92e4.04
(2H, 2m, H20), 7.61e7.67 (6H, m, H50), 7.71e7.78 (9H, m, H40, H60),
7.71e7.78; 13C NMR (125 MHz, CDCl3): d (ppm) 12.2 (C11), 13.6 (C9),
14.6 (C10), 17.4 (1C, d, JCP¼53.4 Hz, C20), 20.3 (C4), 23.9 (C12), 30.5
(C3), 31.0 (1C, d, JCCP¼3.8 Hz, C10), 38.8 (C100), 39.5 (C1000), 75.2 (1C, d,
JC3P¼13.9 Hz, C2), 118.1 (C4a), 118.3 (1C, d, JCP¼86.1 Hz, C15), 123.3,129.1 (1C, 2 s, C7, C8), 127.8 (C5), 130.5 (6C, d, JC3P¼12.8, C50), 133.6
(6C, d, JCCP¼10.1 Hz, C40), 135.1 (3C, d, JC4P¼3.0 Hz, C60), 139.8 (C6),
149.3 (C8a); 31P NMR (121 MHz, CDCl3): d (ppm) 27.0.
4.2.13. (2-(6-Hydroxy-2,5,7,8-tetramethyl-chromen-2-yl)ethyl)tri-
phenylphosphonium methanesulfonate, MitoE2 (1). A solution of
lithium diisopropylamide was prepared by adding diisopropyl-
amine (0.30 mL, 0.216 g, 2.13 mmol) to anhydrous THF (4 mL) at
78 C followed by n-BuLi (1.8 M in hexane, 1.0 mL, 1.8 mmol). The
solutionwas stirred at78 C for 30min and then allowed towarm
to 0 C. The lithium diisopropylamide solution was then added to
a solution of 26 (0.195 g, 0.29 mmol) in anhydrous THF (4 mL) with
stirring at 0 C. After 30 min the solution was allowed to warm to
room temperature and then aqueous saturated NH4OMs (10 mL)
was added. The aqueous layer was extractedwith CH2Cl2 (310mL)
and the combined organic phases dried over anhydrous MgSO4,
ﬁltered and concentrated in vacuo to give a pale yellow oil (1.003 g).
The crude product was dissolved in CH2Cl2 (0.5 mL) and pre-
cipitated from Et2O (20 mL) twice then chromatographed on silica
gel with elution with 1:9 EtOH:CH2Cl2 and ﬁnally passed through
an anion exchange column loaded with OMs in methanol. The
residual solvents were removed by freeze drying to give 1 as
a white solid (52.8 mg, 89.3 mmol, 31%). HRMS (þve ESI) m/z calcd
for [M]þ: 495.2459, found: 495.2462; 1H NMR (500 MHz, CD2Cl2):
d (ppm) 1.37 (3H, s, H12), 1.87 (2H, t, J¼7.0 Hz, H3), 1.69e1.78,
1.93e2.02 (2H, 2 m, H10), 2.03 (3H, s, H11), 2.06 (3H, s, H9), 2.15
(3H, s, H10), 2.39e2.48, 2.53e2.62 (2H, 2 m, H4), 2.60 (3H, s,
H1000), 3.04e3.22, 3.28e3.46 (2H, 2 m, H20), 3.70 (1H, s (br), H100),
7.53 (6H, dd, J¼12.7, 7.6 Hz, H40), 7.63 (6H, td, J¼7.7, 3.5 Hz, H50),
7.83 (3H, t, J¼7.4 Hz,H60); 13C NMR (125MHz, CD2Cl2): d (ppm) 11.7
(C9), 12.0 (C11), 12.7 (C10), 17.9 (1C, d, JCP¼54.8 Hz, C20), 20.7 (C4),
24.4 (C12), 29.9 (C10), 32.0 (C3), 39.7 (3C, s, C1000), 73.7 (1C, d,
JC3P¼13.5 Hz, C2), 117.4 (C4a), 118.1 (1C, d, JCP¼86.4 Hz, C30), 120.7
(C5), 122.0, 123.0 (1C, 2 s, C7, C8), 130.9 (6C, d, JC3P¼12.9, C50),
133.6 (6C, d, JCCP¼9.8 Hz, C40), 135.8 (3C, d, JC4P¼3.1 Hz, C60), 144.2
(C8a), 146.6 (C6); 31P NMR (121 MHz, CD2Cl2): d (ppm) 26.1.
4.2.14. (4-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-yl)-butyl)tri-
phenylphosphonium methanesulfonate, MitoE4 (2). A solution of
lithium diisopropylamide (2.07 mmol) in anhydrous THF (4.0 mL)
was prepared as for 2 above and added to a solution of 24 (0.192 g,
0.28 mmol) in anhydrous THF (4.0 mL) stirring at 0 C. After 30 min
the solutionwas allowed towarm up to room temperature and then
aqueous saturated NH4OMs (10 mL) was added. The aqueous layer
was extractedwith CH2Cl2 (310mL). The combined organic phases
were dried over anhydrous MgSO4, ﬁltered and concentrated in
vacuo to give a pale yellow oil. The crude product was dissolved in
CH2Cl2 (0.5 mL) and precipitated from Et2O (20 mL) twice and then
puriﬁed by column chromatography on silica gel and elution with
1:9 EtOH:CH2Cl2 to afford 2 as a white solid (0.091 g, 0.15 mmol,
53%). TLC: Rf 0.22 (1:9 EtOH:CH2Cl2); HRMS (þve ESI) m/z calcd for
[M]þ: 523.2760, found: 523.2771; 1H NMR (500 MHz, CD2Cl2)
d (ppm) 1.18 (3H, s, H12), 1.42e1.66 (2H, m, H10), 1.66e1.79 (6H, m,
H3,H20,H30),1.94 (3H, s,H11), 2.07 (3H, s,H9), 2.08 (3H, s,H10), 2.55
(2H, t, J¼6.8 Hz, H4), 2.61 (3H, s, H1000), 3.14e3.24 (2H, m, H40), 3.47
(1H, s, H100), 7.62e7.72 (12H, m, H60, H70), 7.84 (3H, t J¼7.3 Hz, H80);
13C NMR (125 MHz) CD2Cl2: d (ppm) 11.6 (C9), 11.9 (C11), 12.5 (C10),
21.0 (C4), 23.0 (1C, d, JCP¼50.6Hz,C40), 23.2 (C30), 24.1 (C12) 25.1 (1C,
d, JC3P¼15.9 Hz, C20), 32.1 (C3), 38.2 (C10), 39.6 (C1000), 74.3 (C2), 117.6
(C4a),118.3 (1C, d, JCP¼85.6Hz,C50),119.7 (C5),122.0,122.2 (2C, 2 s,
C7, C8),130.9 (6C, d, JC3P¼12.5Hz, C70),133.8 (6C, d, JCCP¼9.8Hz, C60),
135.7 (3C, d, JC4P¼2.6 Hz, C80), 145.2 (C6), 145.5 (C8a); 31P NMR
(121 MHz, CD2Cl2): d (ppm) 24.8.
4.2.15. (6-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-yl)-hexyl)tri-
phenyl phosphonium methanesulfonate, MitoE6 (3). A solution of
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was prepared as for 2 above and added to a solution of 22 (0.152 g,
0.21 mmol) in anhydrous THF (10 mL) with stirring at 0 C. After
30 min the solutionwas allowed to warm to room temperature and
then aqueous saturated NH4OMs (10 mL) was added. The aqueous
layer was extracted with CH2Cl2 (31 mL). The combined organic
phases were dried over anhydrous MgSO4, ﬁltered and concen-
trated in vacuo to give a pale yellow oil which was dissolved in
CH2Cl2 (0.5 mL) and precipitated from Et2O (20 mL) twice. Puriﬁ-
cation by column chromatography on silica gel and elutionwith 1:9
EtOH:CH2Cl2 followed by freeze drying gave 3 as a white solid
(0.067 g, 0.10 mmol, 49%). TLC: Rf 0.19 (1:9 EtOH:CH2Cl2); HRMS
(þve ESI) m/z calcd for [M]þ: 551.3073, found: 551.3078; 1H NMR
(500 MHz, CD2Cl2): d (ppm) 1.17 (3H, s, H12), 1.24e1.27 (4H, m, H20,
H30), 1.42e1.57 (4H, m, H10, H40), 1.57e1.66 (2H, m, H50), 1.66e1.80
(2H, m,H3), 2.00 (3H, s,H11), 2.07 (3H, s,H9), 2.10 (3H, s,H10), 2.50
(3H s, H1000), 2.55 (2H, t, J¼6.9 Hz, H4), 3.22e3.30 (2H, m, H60),
7.66e7.77 (12H, m, H80, H90), 7.82e7.86 (3H, m, H100); 13C NMR
(125 MHz, CD2Cl2): d (ppm) 11.6 (C9), 11.9 (C11), 12.8 (C10), 21.0
(C4), 22.86 (1C, d, JCCP¼4.5 Hz, C50), 22.9 (1C, d, JCP¼50.9 Hz, C60),
23.5 (C20), 24.0 (C12), 29.7 (C30), 30.8 (1C, d, JC3P¼16.1 Hz, C40), 30.1
(C3), 39.7 (C10), 39.0 (C1000), 75.6 (C2), 117.7 (C4a), 118.3 (1C, d,
JCP¼85.5 Hz, C70),119.5 (C5),121.8,122.4 (2C, 2 s, C7, C8),130.9 (6C,
d, JC3P¼12.6 Hz, C90), 133.9 (6C, d, JCCP¼9.9 Hz, C80), 135.6 (3C, d,
JC4P¼3.3 Hz, C100), 145.3 (C6), 145.6 (C8a); 31P NMR (121 MHz,
CD2Cl2): d (ppm) 24.8.
4.2.16. (10-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-yl)-decyl)tri-
phenylphosphonium methanesulfonate, MitoE10 (4). A mixture of
10-(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-chromen-2-yl)
decyl methanesulfonate (S7, Supplementary data) (0.095 g,
0.21 mmol) and triphenylphosphine (0.282 g, 1.07 mmol) was
mixed in a Kimax tube then the tube was ﬂushed with argon,
sealed and stirred at 80 C for 24 h. The tube was then cooled and
crude product dissolved in CH2Cl2 (0.5 mL) and precipitated twice
from Et2O to give a pale yellow oil (0.027 g). The oil was dissolved
in EtOH (0.5 mL) and then diluted with H2O (5 mL) and any vol-
atile solvents were removed in vacuo. The aqueous solution was
freeze dried to give 4 as a ﬂuffy white solid (27.0 mg, 37.4 mmol,
18%). HRMS (þve ESI) m/z calcd for [M]þ: 607.3699, found:
607.3687; 1H NMR (500 MHz, CD2Cl2) d (ppm) 1.26e1.30 (8H, m,
H30eH60) 1.20 (3H, s, H12), 1.34e1.46 (2H, m, H20), 1.46e1.57 (4H,
H10, H70), 1.57e1.67 (4H, m, H80, H90), 1.69e1.81 (2H, m, H3), 2.04
(3H, s, H11), 2.06 (3H, s, H9), 2.10 (3H, s, H10), 2.53 (3H, s, H1000),
2.56 (2H, t, J¼6.8 Hz, H4), 3.25e3.31 (2H, m, H100), 7.68e7.73 (12H,
m, H120, H130), 7.81e7.85 (3H, m, H140); 13C NMR (125 MHz)
CD2Cl2: d (ppm) 11.6 (C9) 11.9 (C11), 12.6 (C10), 21.1 (C4), 22.8 (1C,
d, JCP¼50.4 Hz, C100), 22.8 (1C, d, JCCP¼4.5 Hz, C90), 23.6 (C20) 24.2
(C12), 29.2, 29.5, 30.2 (3C, 5 s, C30eC70), 30.9 (1C, d, JC3P¼16.0 Hz,
C80), 32.2 (C3), 38.8 (C10), 39.7 (H1000), 74.6 (C2), 117.7 (C4a), 118.5
(1C, d, JCP¼85.5 Hz, C110), 119.5 (C5), 121.9, 122.4 (2C, 2 s, C7, C8),
130.8 (1C, d, JC3P¼12.5 Hz, C130), 133.9 (1C, d, JCCP¼10.1 Hz, C120),
135.5 (1C, d, JC4P¼2.8 Hz, C140), 145.4 (C6), 145.5 (C8a); 31P NMR
(121 MHz) CD2Cl2: d (ppm) 24.9.
4.2.17. (11-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-yl)-undecyl)
triphenylphosphonium methanesulfonate, MitoE11 (5). A mixture of
11-(6-Hydroxy-2,5,7,8-tetramethyl-chromen-2-yl)undecyl meth-
anesulfonate (S11, Supplementary data) (0.097 g, 0.21 mmol) and
triphenylphosphine (0.285 g, 1.09 mmol) was placed in a Kimax
tube, which was ﬂushed with argon, sealed and stirred at 80 C for
48 h. The cooled reaction mixture was dissolved in CH2Cl2 (0.5 mL)
and precipitated twice from Et2O to give 5 as a pale yellow oil
(0.087 g, 0.12mmol, 57%). LRMS (þve ESI) calcd for [M]þ: 621, found
621; HRMS (þve ESI) calcd for [M]þ: 621.3856, found 621.3853; 1H
NMR (500MHz, CDCl3) d (ppm) 1.15 (12H, s (br), H30eH80) 1.20 (3H,s, H12), 1.36 (2H, quin, J¼7.3 Hz, H20), 1.42e1.58 (2H, m, H10),
1.52e1.60 (4H, m, H90, H100), 1.69e1.81 (2H, m, H3), 2.07 (3H, s,
H11), 2.09 (3H, s, H9), 2.12 (3H, s, H10), 2.56 (2H, t, J¼6.8 Hz, H4),
2.69 (3H, s, H1000), 3.53 (2H, m, H110), 7.66e7.72 (6H, m, H140),
7.74e7.81 (9H, m, H130, H150); 13C NMR (125 MHz) CDCl3: d (ppm)
11.5 (C9) 11.8 (C11), 12.4 (C10), 20.8 (C4), 21.5 (1C, d, JCP¼50.0 Hz,
C110), 22.7 (1C, d, JCCP¼4.5 Hz, C100), 23.5 (C20) 24.0 (C12), 29.2,
29.3(9), 29.4(1), 29.5, 30.0 (6C, 5 s, C30eC80), 30.4 (1C, d,
JC3P¼15.6 Hz, C90), 31.7 (C3), 39.0 (C10), 39.5 (H1000), 74.4 (C2), 117.3
(C4a), 118.6 (1C, d, JCP¼85.6 Hz, C120), 119.0 (C5), 121.5,122.4 (2C, 2
s, C7, C8), 144.9 (C6), 145.4 (C8a), 130.5 (1C, d, JC3P¼12.3 Hz, C140),
133.6 (1C, d, JCCP¼9.8 Hz, C130), 135.0 (1C, d, JC4P¼2.9 Hz, C150); 31P
NMR (121 MHz) CDCl3: d (ppm) 25.4.4.3. Measurement of lipid peroxidation rat brain
homogenates
Rat brain homogenates were prepared and incubated for 30 min
at 37 C as described23 with a range of concentration of MitoE
compounds, Trolox or ethanol carrier. The extent of lipid perox-
idationwas assessed by measuring TBARS.22 Values were corrected
for the background level at t¼0 and were expressed as a % of the
control with EtOH carrier. Data are the meansSD of 4e6 in-
dependent experiments.4.4. Mitochondrial and cell experiments
Rat liver mitochondria were prepared as described.22 Mito-
chondrial uptake of MitoE2, MitoE10 was measured using an ion-
selective electrode for TPP, as previously described21 Brieﬂy, iso-
lated rat liver mitochondria (1 mg protein/mL) were incubated in
120mMKCl, 10 mMHEPES,1 mM EGTA, pH 7.2, KOH supplemented
with 4 mg/mL rotenone at 37 C with stirring. The TPP-electrode
response was calibrated with ﬁve successive additions of 1 mM
MitoE2 or MitoE10 (from a 1 mM stock in EtOH). The mitochondria
were energised with 10 mM succinate as a respiratory substrate to
induce membrane potential-dependent uptake of the MitoE com-
pound into the mitochondrial matrix. Finally the mitochondria
were uncoupled with 1 mM FCCP, dissipating the membrane po-
tential and resulting in release of MitoE.
To measure mitochondrial lipid peroxidation, isolated rat liver
mitochondria (2 mg protein/mL) were incubated in KCl medium as
above, supplemented with 10 mM succinate and 4 mg/mL rotenone
at 37 C and pretreatedMitoE for 2 min. Lipid peroxidation was
then initiated with 1 mM cumene hydroperoxide, and the mito-
chondria were incubated for a further 15 min. Lipid peroxidation
was assayed as TBARS as above. Values were corrected for back-
ground level without cumene hydroperoxide and were expressed
as a % of the control with EtOH carrier. Data are the meansSD of
3e4 independent experiments.
To measure mitochondrial DNA damage, C2C12 cells were
seeded at 20,000 cells/cm2 in six-well culture plates and grown
overnight at 37 C. Cells were then pre-incubated in 100 nM
MitoE10 or n-decyltriphenylphosphonium bromide (decylTPP) for
30 min, and then 25 mM menadione was added to generate oxi-
dative damage within the cells and incubated for a further 1 h. Cells
were washed and DNA was isolated using the DNeasy Blood and
Tissue kit from Qiagen, quantitated using the Picogreen Assay
(Invitrogen), and then the extent of oxidative damage was assessed
by a quantitative PCR assay comparing the relative ampliﬁcation of
a long (w10 kbp) of mitochondrial DNA normalised to a short
(w100 bp) section as described. Data are expressed relative to
untreated cells and are meansSEM of three independent
V.J.A. Jameson et al. / Tetrahedron 71 (2015) 8444e8453 8453experiments. Statistical signiﬁcancewas determined by Student’s t-
test. **p<0.01 compared against menadione treated samples.
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